Arrowhead Pharmaceuticals Dives On Safety Issues For ARO-ENaC, But Remains On Track In Other Indications
DavidBGray/E+ via Getty Images
Arrowhead Pharmaceuticals (ARWR) fell by 25% this past Friday, when it announced that there was a safety issue that occurred in an animal study for its drug ARO-ENaC for the treatment of patients with Cystic Fibrosis. The…
